# A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

> **NCT00162071** · PHASE2 · TERMINATED · sponsor: **Forest Laboratories** · enrollment: 20 (—)

## Conditions studied

- Cardiovascular Disease
- Ischemic Heart Disease

## Interventions

- **DRUG:** apadenoson

## Key facts

- **NCT ID:** NCT00162071
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 20 (—)
- **Why stopped:** Sponsor decided not to continue with the development program
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162071, "A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00162071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*